The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
- PMID: 21852788
- DOI: 10.1038/nrd3505
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
Abstract
The amyloid cascade hypothesis, which posits that the deposition of the amyloid-β peptide in the brain is a central event in Alzheimer's disease pathology, has dominated research for the past twenty years. Several therapeutics that were purported to reduce amyloid-β production or aggregation have failed in Phase III clinical testing, and many others are in various stages of development. Therefore, it is timely to review the science underpinning the amyloid cascade hypothesis, consider what type of clinical trials will constitute a valid test of this hypothesis and explore whether amyloid-β-directed therapeutics will provide the medicines that are urgently needed by society for treating this devastating disease.
Similar articles
-
Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer's Disease Immunotherapy.Drugs Aging. 2016 Oct;33(10):685-697. doi: 10.1007/s40266-016-0406-x. Drugs Aging. 2016. PMID: 27699633 Review.
-
Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease.Brain. 2014 Mar;137(Pt 3):887-903. doi: 10.1093/brain/awt362. Epub 2014 Feb 10. Brain. 2014. PMID: 24519982
-
On the origin of Alzheimer's disease. Trials and tribulations of the amyloid hypothesis.Ageing Res Rev. 2014 Jan;13:10-2. doi: 10.1016/j.arr.2013.10.001. Epub 2013 Nov 16. Ageing Res Rev. 2014. PMID: 24252390 Review.
-
Perspective: prevention is better than cure.Nature. 2011 Jul 13;475(7355):S15. doi: 10.1038/475S15a. Nature. 2011. PMID: 21760576 Free PMC article.
-
Alzheimer's disease amyloid hypothesis at crossroads: where do we go from here?Expert Opin Ther Targets. 2010 Dec;14(12):1273-7. doi: 10.1517/14728222.2010.528285. Expert Opin Ther Targets. 2010. PMID: 21058918
Cited by
-
Comparison of Cognitive Impairment Diagnosis Criteria in Clinical Settings: Conventional vs. Neuropsychological.Alpha Psychiatry. 2024 Mar 1;25(2):212-219. doi: 10.5152/alphapsychiatry.2024.231448. eCollection 2024 Mar. Alpha Psychiatry. 2024. PMID: 38798819 Free PMC article.
-
Inhibition of Amyloid-β (Aβ)-Induced Cognitive Impairment and Neuroinflammation in CHI3L1 Knockout Mice through Downregulation of ERK-PTX3 Pathway.Int J Mol Sci. 2024 May 19;25(10):5550. doi: 10.3390/ijms25105550. Int J Mol Sci. 2024. PMID: 38791588 Free PMC article.
-
Electroacupuncture regulates Rab5a-mediating NGF transduction to improve learning and memory ability in the early stage of AD mice.CNS Neurosci Ther. 2024 May;30(5):e14743. doi: 10.1111/cns.14743. CNS Neurosci Ther. 2024. PMID: 38780008 Free PMC article.
-
Alzheimer's disease manifests abnormal sphingolipid metabolism.Front Aging Neurosci. 2024 May 7;16:1368839. doi: 10.3389/fnagi.2024.1368839. eCollection 2024. Front Aging Neurosci. 2024. PMID: 38774265 Free PMC article.
-
Transcranial Magneto-Acoustic Stimulation Protects Synaptic Rehabilitation from Amyloid-Beta Plaques via Regulation of Microglial Functions.Int J Mol Sci. 2024 Apr 24;25(9):4651. doi: 10.3390/ijms25094651. Int J Mol Sci. 2024. PMID: 38731870 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous